{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:18:20Z","timestamp":1767849500362,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.tranon.2023.101650","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T11:51:31Z","timestamp":1678621891000},"page":"101650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immunotherapeutic potential of blinatumomab-secreting \u03b39\u03b42 T Cells"],"prefix":"10.1016","volume":"31","author":[{"given":"Shang-Ju","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-4505","authenticated-orcid":false,"given":"Chien-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng Hao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2023.101650_bib0001","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11899-021-00628-2","article-title":"Chimeric antigen receptor-modified T cells and T cell-engaging bispecific antibodies: different tools for the same job","volume":"16","author":"Schwerdtfeger","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.tranon.2023.101650_bib0002","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/bloodadvances.2020003554","article-title":"CAR T cells better than BiTEs","volume":"5","author":"Molina","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2023.101650_bib0003","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2023.101650_bib0004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Wu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2023.101650_bib0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.tranon.2023.101650_bib0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.tranon.2023.101650_bib0007","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.tranon.2023.101650_bib0008","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tranon.2023.101650_bib0009","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2023.101650_bib0010","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2023.101650_bib0011","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-21-0853","article-title":"Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers","volume":"10","author":"Blanco","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tranon.2023.101650_bib0012","doi-asserted-by":"crossref","first-page":"27130","DOI":"10.1038\/srep27130","article-title":"T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive Malignancies","volume":"6","author":"Velasquez","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2023.101650_bib0013","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1038\/bcj.2016.38","article-title":"Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2023.101650_bib0014","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.tranon.2023.101650_bib0015","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-celltherapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2023.101650_bib0016","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3389\/fimmu.2020.01792","article-title":"Engineering immune cells for in vivo secretion of tumor-specific T cell-redirecting bispecific antibodies","volume":"11","author":"Blanco","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2023.101650_bib0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/cmi.2012.43","article-title":"gammadelta-T cells: an unpolished sword in human anti-infection immunity","volume":"10","author":"Zheng","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.tranon.2023.101650_bib0018","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00018-011-0698-2","article-title":"Searching for \"signal 2\": costimulation requirements of gammadelta T cells","volume":"68","author":"Ribot","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tranon.2023.101650_bib0019","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93179","article-title":"Adoptively transferred Vgamma9Vdelta2 T cells show potent anti-tumor effects in a preclinical B cell lymphomagenesis model","volume":"2","author":"Zumwalde","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.tranon.2023.101650_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040829","article-title":"Vgamma9Vdelta2 T cells: can we re-purpose a potent anti-infection mechanism for cancer therapy?","volume":"9","author":"Kunkele","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2023.101650_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223572","article-title":"Human Vdelta2 T cells and their versatility for immunotherapeutic approaches","volume":"11","author":"Sanz","year":"2022","journal-title":"Cells."},{"key":"10.1016\/j.tranon.2023.101650_bib0022","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.4049\/jimmunol.181.9.5857","article-title":"NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short- versus long-term cultured human gamma delta lymphocytes","volume":"181","author":"Ferrarini","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2023.101650_bib0023","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2021.08.005","article-title":"Human Vgamma9Vdelta2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells","volume":"573","author":"Tomogane","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tranon.2023.101650_bib0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CJI.0000000000000187","article-title":"Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma","volume":"40","author":"Huang","year":"2017","journal-title":"J. Immunother."},{"key":"10.1016\/j.tranon.2023.101650_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-12-45","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells","volume":"12","author":"Wilhelm","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2023.101650_bib0026","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2023.101650_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-1759(00)00329-X","article-title":"A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis","volume":"249","author":"Sheehy","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tranon.2023.101650_bib0028","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1038\/s41598-021-91784-1","article-title":"The potential of adoptive transfer of gamma9delta2 T cells to enhance blinatumomab's anti-tumor activity against B-cell malignancy","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2023.101650_bib0029","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Clendening","year":"2010","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tranon.2023.101650_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2023.101650_bib0031","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.tranon.2023.101650_bib0032","doi-asserted-by":"crossref","unstructured":"Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et\u00a0al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer immunology, immunotherapy: CII. 2011;60:1447-60. doi:10.1007\/s00262-011-1049-8.","DOI":"10.1007\/s00262-011-1049-8"},{"key":"10.1016\/j.tranon.2023.101650_bib0033","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","article-title":"Cell-redirecting strategies to 'STAb' tumors: beyond CARs and bispecific antibodies","volume":"40","author":"Blanco","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.tranon.2023.101650_bib0034","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.scr.2017.01.010","article-title":"Ex vivo expansion of CD3(depleted) cord blood-MNCs in the presence of bone marrow stromal cells; an appropriate strategy to provide functional NK cells applicable for cellular therapy","volume":"19","author":"Hosseini","year":"2017","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.tranon.2023.101650_bib0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humimm.2021.09.004","article-title":"Exhausted NK cells and cytokine storms in COVID-19: whether NK cell therapy could be a therapeutic choice","volume":"83","author":"Ghasemzadeh","year":"2022","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.tranon.2023.101650_bib0036","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-17-0171","article-title":"CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells","volume":"5","author":"Velasquez","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tranon.2023.101650_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126086","article-title":"DNA-encoded bispecific T cell engagers and antibodies present long-term anti-tumor activity","volume":"4","author":"Perales-Puchalt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.tranon.2023.101650_bib0038","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13046-019-1354-1","article-title":"A novel asymmetrical anti-HER2\/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells","volume":"38","author":"Yu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2023.101650_bib0039","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.omto.2022.07.003","article-title":"In vivo DNA-launched bispecific T cell engager targeting IL-13Ralpha2 controls tumor growth in an animal model of glioblastoma multiforme","volume":"26","author":"Bhojnagarwala","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.tranon.2023.101650_bib0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Therapy"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:25:47Z","timestamp":1761845147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523323000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"alternative-id":["S1936523323000360"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101650","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic potential of blinatumomab-secreting \u03b39\u03b42 T Cells","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101650"}}